APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biosimilar Insulin Glargine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Biosimilar Insulin Glargine Industry Growth and Trends Forecast to 2032

Report ID 17397091012 January 202690 pages

Choose your research edition.

Industry ResearchBiosimilar Insulin Glargine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilar Insulin Glargine Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Biosimilar Insulin Glargine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilar Insulin Glargine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilar Insulin Glargine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Biosimilar Insulin Glargine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Biosimilar Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Biosimilar Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biosimilar Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Biosimilar Insulin Glargine include Biocon, Gan&Lee, Geropharm, United Laboratory, Wockhardt, Eli Lilly and Tonghua Dongbao, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Biosimilar Insulin Glargine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Biosimilar Insulin Glargine market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Biosimilar Insulin Glargine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Biosimilar Insulin Glargine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Biosimilar Insulin Glargine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Biosimilar Insulin Glargine Market by Company

Biocon

Gan&Lee

Geropharm

United Laboratory

Wockhardt

Eli Lilly

Tonghua Dongbao

Biosimilar Insulin Glargine Segment by Type

Pre-filled

Cartridge

Biosimilar Insulin Glargine Segment by Application

Hospital

Retail Pharmacy

Others

Biosimilar Insulin Glargine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Insulin Glargine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Insulin Glargine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Insulin Glargine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biosimilar Insulin Glargine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Biosimilar Insulin Glargine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Pre-filled Table 2. Major Company of Cartridge Table 3. Global Biosimilar Insulin Glargine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Biosimilar Insulin Glargine Sales by Type (2021-2026) & (K Units) Table 5. Global Biosimilar Insulin Glargine Sales Market Share in Volume by Type (2021-2026) Table 6. Global Biosimilar Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 7. Global Biosimilar Insulin Glargine Sales Market Share in Value by Type (2021-2026) Table 8. Global Biosimilar Insulin Glargine Price by Type (2021-2026) & (US$/Unit) Table 9. Global Biosimilar Insulin Glargine Sales by Type (2027-2032) & (K Units) Table 10. Global Biosimilar Insulin Glargine Sales Market Share in Volume by Type (2027-2032) Table 11. Global Biosimilar Insulin Glargine Sales by Type (2027-2032) & (US$ Million) Table 12. Global Biosimilar Insulin Glargine Sales Market Share in Value by Type (2027-2032) Table 13. Global Biosimilar Insulin Glargine Price by Type (2027-2032) & (US$/Unit) Table 14. North America Biosimilar Insulin Glargine Sales by Type (2021-2026) & (K Units) Table 15. North America Biosimilar Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Biosimilar Insulin Glargine Sales by Type (2021-2026) & (K Units) Table 17. Europe Biosimilar Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Biosimilar Insulin Glargine Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Biosimilar Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Biosimilar Insulin Glargine Sales by Type (2021-2026) & (K Units) Table 21. Latin America Biosimilar Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Biosimilar Insulin Glargine Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Biosimilar Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 24. Biosimilar Insulin Glargine Industry Trends Table 25. Biosimilar Insulin Glargine Industry Drivers Table 26. Biosimilar Insulin Glargine Industry Opportunities and Challenges Table 27. Biosimilar Insulin Glargine Industry Restraints Table 28. Global Biosimilar Insulin Glargine Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Biosimilar Insulin Glargine Revenue Market Share by Company (2021-2026) Table 30. Global Biosimilar Insulin Glargine Sales by Company (2021-2026) & (K Units) Table 31. Global Biosimilar Insulin Glargine Sales Share by Company (2021-2026) Table 32. Global Biosimilar Insulin Glargine Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Biosimilar Insulin Glargine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Biosimilar Insulin Glargine Major Company Production Sites and Headquarters Table 35. Global Biosimilar Insulin Glargine Company, Product Type & Application Table 36. Global Biosimilar Insulin Glargine Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Biosimilar Insulin Glargine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Biosimilar Insulin Glargine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Biosimilar Insulin Glargine Sales by Region (2021-2026) & (K Units) Table 41. Global Biosimilar Insulin Glargine Sales Market Share in Volume by Region (2021-2026) Table 42. Global Biosimilar Insulin Glargine Sales by Region (2021-2026) & (US$ Million) Table 43. Global Biosimilar Insulin Glargine Sales Market Share in Value by Region (2021-2026) Table 44. Global Biosimilar Insulin Glargine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Biosimilar Insulin Glargine Sales by Region (2027-2032) & (K Units) Table 46. Global Biosimilar Insulin Glargine Sales Market Share in Volume by Region (2027-2032) Table 47. Global Biosimilar Insulin Glargine Sales by Region (2027-2032) & (US$ Million) Table 48. Global Biosimilar Insulin Glargine Sales Market Share in Value by Region (2027-2032) Table 49. Global Biosimilar Insulin Glargine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Biosimilar Insulin Glargine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Biosimilar Insulin Glargine Sales by Application (2021-2026) & (K Units) Table 52. Global Biosimilar Insulin Glargine Sales Market Share in Volume by Application (2021-2026) Table 53. Global Biosimilar Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 54. Global Biosimilar Insulin Glargine Sales Market Share in Value by Application (2021-2026) Table 55. Global Biosimilar Insulin Glargine Price by Application (2021-2026) & (US$/Unit) Table 56. Global Biosimilar Insulin Glargine Sales by Application (2027-2032) & (K Units) Table 57. Global Biosimilar Insulin Glargine Sales Market Share in Volume by Application (2027-2032) Table 58. Global Biosimilar Insulin Glargine Sales by Application (2027-2032) & (US$ Million) Table 59. Global Biosimilar Insulin Glargine Sales Market Share in Value by Application (2027-2032) Table 60. Global Biosimilar Insulin Glargine Price by Application (2027-2032) & (US$/Unit) Table 61. North America Biosimilar Insulin Glargine Sales by Application (2021-2026) & (K Units) Table 62. North America Biosimilar Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Biosimilar Insulin Glargine Sales by Application (2021-2026) & (K Units) Table 64. Europe Biosimilar Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Biosimilar Insulin Glargine Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Biosimilar Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Biosimilar Insulin Glargine Sales by Application (2021-2026) & (K Units) Table 68. Latin America Biosimilar Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Biosimilar Insulin Glargine Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Biosimilar Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 71. Biocon Company Information Table 72. Biocon Business Overview Table 73. Biocon Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Biocon Biosimilar Insulin Glargine Product Portfolio Table 75. Biocon Recent Development Table 76. Gan&Lee Company Information Table 77. Gan&Lee Business Overview Table 78. Gan&Lee Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Gan&Lee Biosimilar Insulin Glargine Product Portfolio Table 80. Gan&Lee Recent Development Table 81. Geropharm Company Information Table 82. Geropharm Business Overview Table 83. Geropharm Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Geropharm Biosimilar Insulin Glargine Product Portfolio Table 85. Geropharm Recent Development Table 86. United Laboratory Company Information Table 87. United Laboratory Business Overview Table 88. United Laboratory Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. United Laboratory Biosimilar Insulin Glargine Product Portfolio Table 90. United Laboratory Recent Development Table 91. Wockhardt Company Information Table 92. Wockhardt Business Overview Table 93. Wockhardt Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Wockhardt Biosimilar Insulin Glargine Product Portfolio Table 95. Wockhardt Recent Development Table 96. Eli Lilly Company Information Table 97. Eli Lilly Business Overview Table 98. Eli Lilly Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Eli Lilly Biosimilar Insulin Glargine Product Portfolio Table 100. Eli Lilly Recent Development Table 101. Tonghua Dongbao Company Information Table 102. Tonghua Dongbao Business Overview Table 103. Tonghua Dongbao Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Tonghua Dongbao Biosimilar Insulin Glargine Product Portfolio Table 105. Tonghua Dongbao Recent Development Table 106. North America Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 107. North America Biosimilar Insulin Glargine Sales by Country (2021-2026) & (K Units) Table 108. North America Biosimilar Insulin Glargine Sales Market Share by Country (2021-2026) Table 109. North America Biosimilar Insulin Glargine Sales Forecast by Country (2027-2032) & (K Units) Table 110. North America Biosimilar Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 111. North America Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 112. North America Biosimilar Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 113. North America Biosimilar Insulin Glargine Market Share by Country (2021-2026) Table 114. North America Biosimilar Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 115. North America Biosimilar Insulin Glargine Market Share Forecast by Country (2027-2032) Table 116. Europe Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 117. Europe Biosimilar Insulin Glargine Sales by Country (2021-2026) & (K Units) Table 118. Europe Biosimilar Insulin Glargine Sales Market Share by Country (2021-2026) Table 119. Europe Biosimilar Insulin Glargine Sales Forecast by Country (2027-2032) & (K Units) Table 120. Europe Biosimilar Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 121. Europe Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. Europe Biosimilar Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 123. Europe Biosimilar Insulin Glargine Market Share by Country (2021-2026) Table 124. Europe Biosimilar Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. Europe Biosimilar Insulin Glargine Market Share Forecast by Country (2027-2032) Table 126. Asia-Pacific Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 127. Asia-Pacific Biosimilar Insulin Glargine Sales by Country (2021-2026) & (K Units) Table 128. Asia-Pacific Biosimilar Insulin Glargine Sales Market Share by Country (2021-2026) Table 129. Asia-Pacific Biosimilar Insulin Glargine Sales Forecast by Country (2027-2032) & (K Units) Table 130. Asia-Pacific Biosimilar Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 131. Asia-Pacific Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Asia-Pacific Biosimilar Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 133. Asia-Pacific Biosimilar Insulin Glargine Market Share by Country (2021-2026) Table 134. Asia-Pacific Biosimilar Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Asia-Pacific Biosimilar Insulin Glargine Market Share Forecast by Country (2027-2032) Table 136. Latin America Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 137. Latin America Biosimilar Insulin Glargine Sales by Country (2021-2026) & (K Units) Table 138. Latin America Biosimilar Insulin Glargine Sales Market Share by Country (2021-2026) Table 139. Latin America Biosimilar Insulin Glargine Sales Forecast by Country (2027-2032) & (K Units) Table 140. Latin America Biosimilar Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 141. Latin America Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Latin America Biosimilar Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 143. Latin America Biosimilar Insulin Glargine Market Share by Country (2021-2026) Table 144. Latin America Biosimilar Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Latin America Biosimilar Insulin Glargine Market Share Forecast by Country (2027-2032) Table 146. Middle East and Africa Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 147. Middle East and Africa Biosimilar Insulin Glargine Sales by Country (2021-2026) & (K Units) Table 148. Middle East and Africa Biosimilar Insulin Glargine Sales Market Share by Country (2021-2026) Table 149. Middle East and Africa Biosimilar Insulin Glargine Sales Forecast by Country (2027-2032) & (K Units) Table 150. Middle East and Africa Biosimilar Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 151. Middle East and Africa Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Middle East and Africa Biosimilar Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 153. Middle East and Africa Biosimilar Insulin Glargine Market Share by Country (2021-2026) Table 154. Middle East and Africa Biosimilar Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Middle East and Africa Biosimilar Insulin Glargine Market Share Forecast by Country (2027-2032) Table 156. Key Raw Materials Table 157. Raw Materials Key Suppliers Table 158. Biosimilar Insulin Glargine Distributors List Table 159. Biosimilar Insulin Glargine Customers List Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Biosimilar Insulin Glargine Image Figure 2. Global Biosimilar Insulin Glargine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilar Insulin Glargine Market Size (2021-2032) & (US$ Million) Figure 4. Global Biosimilar Insulin Glargine Sales (2021-2032) & (K Units) Figure 5. Pre-filled Image Figure 6. Global Pre-filled Sales YoY Growth (2021-2032) & (K Units) Figure 7. Cartridge Image Figure 8. Global Cartridge Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Biosimilar Insulin Glargine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Biosimilar Insulin Glargine Market Share by Type 2025 VS 2032 Figure 11. North America Biosimilar Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 12. North America Biosimilar Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 13. Europe Biosimilar Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 14. Europe Biosimilar Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Biosimilar Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Biosimilar Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 17. Latin America Biosimilar Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Biosimilar Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Biosimilar Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Biosimilar Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Biosimilar Insulin Glargine Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Retail Pharmacy Image Figure 26. Global Retail Pharmacy Sales YoY Growth (2021-2032) & (K Units) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Biosimilar Insulin Glargine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Biosimilar Insulin Glargine Market Share by Application 2025 VS 2032 Figure 31. North America Biosimilar Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 32. North America Biosimilar Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 33. Europe Biosimilar Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 34. Europe Biosimilar Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Biosimilar Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Biosimilar Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 37. Latin America Biosimilar Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Biosimilar Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Biosimilar Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Biosimilar Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 41. North America Biosimilar Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Biosimilar Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Biosimilar Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Biosimilar Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Biosimilar Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Biosimilar Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Biosimilar Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Biosimilar Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Biosimilar Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Biosimilar Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Biosimilar Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Biosimilar Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Biosimilar Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Biosimilar Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Biosimilar Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Biosimilar Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Biosimilar Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Biosimilar Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Biosimilar Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Biosimilar Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Biosimilar Insulin Glargine Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Biosimilar Insulin Glargine Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Pre-filled
  • Cartridge
Applications
  • Hospital
  • Retail Pharmacy
  • Others
Companies covered
  • Biocon
  • Gan&Lee
  • Geropharm
  • United Laboratory
  • Wockhardt
  • Eli Lilly
  • Tonghua Dongbao

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biosimilar Insulin Glargine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Biosimilar Insulin Glargine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Biosimilar Insulin Glargine Market by Type
  6. 1.3.1 Pre-filled
  7. 1.3.2 Cartridge
  8. 1.4 Global Biosimilar Insulin Glargine Market Size by Type
  9. 1.4.1 Global Biosimilar Insulin Glargine Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Biosimilar Insulin Glargine Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Biosimilar Insulin Glargine Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Biosimilar Insulin Glargine Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Biosimilar Insulin Glargine Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Biosimilar Insulin Glargine Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Biosimilar Insulin Glargine Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Biosimilar Insulin Glargine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Biosimilar Insulin Glargine Industry Trends
  2. 2.2 Biosimilar Insulin Glargine Industry Drivers
  3. 2.3 Biosimilar Insulin Glargine Industry Opportunities and Challenges
  4. 2.4 Biosimilar Insulin Glargine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Biosimilar Insulin Glargine Revenue (2021-2026)
  2. 3.2 Global Top Players by Biosimilar Insulin Glargine Sales (2021-2026)
  3. 3.3 Global Top Players by Biosimilar Insulin Glargine Price (2021-2026)
  4. 3.4 Global Biosimilar Insulin Glargine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biosimilar Insulin Glargine Major Company Production Sites & Headquarters
  6. 3.6 Global Biosimilar Insulin Glargine Company, Product Type & Application
  7. 3.7 Global Biosimilar Insulin Glargine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biosimilar Insulin Glargine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biosimilar Insulin Glargine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biosimilar Insulin Glargine Tier 1, Tier 2, and Tier 3
4 Biosimilar Insulin Glargine Regional Status and Outlook
  1. 4.1 Global Biosimilar Insulin Glargine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Biosimilar Insulin Glargine Historic Market Size by Region
  3. 4.2.1 Global Biosimilar Insulin Glargine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Biosimilar Insulin Glargine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Biosimilar Insulin Glargine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Biosimilar Insulin Glargine Forecasted Market Size by Region
  7. 4.3.1 Global Biosimilar Insulin Glargine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Biosimilar Insulin Glargine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Biosimilar Insulin Glargine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Biosimilar Insulin Glargine by Application
  1. 5.1 Biosimilar Insulin Glargine Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Others
  5. 5.2 Global Biosimilar Insulin Glargine Market Size by Application
  6. 5.2.1 Global Biosimilar Insulin Glargine Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Biosimilar Insulin Glargine Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Biosimilar Insulin Glargine Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Biosimilar Insulin Glargine Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Biosimilar Insulin Glargine Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Biosimilar Insulin Glargine Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Biosimilar Insulin Glargine Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Biosimilar Insulin Glargine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Biocon
  2. 6.1.1 Biocon Company Information
  3. 6.1.2 Biocon Business Overview
  4. 6.1.3 Biocon Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Biocon Biosimilar Insulin Glargine Product Portfolio
  6. 6.1.5 Biocon Recent Developments
  7. 6.2 Gan&Lee
  8. 6.2.1 Gan&Lee Company Information
  9. 6.2.2 Gan&Lee Business Overview
  10. 6.2.3 Gan&Lee Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Gan&Lee Biosimilar Insulin Glargine Product Portfolio
  12. 6.2.5 Gan&Lee Recent Developments
  13. 6.3 Geropharm
  14. 6.3.1 Geropharm Company Information
  15. 6.3.2 Geropharm Business Overview
  16. 6.3.3 Geropharm Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Geropharm Biosimilar Insulin Glargine Product Portfolio
  18. 6.3.5 Geropharm Recent Developments
  19. 6.4 United Laboratory
  20. 6.4.1 United Laboratory Company Information
  21. 6.4.2 United Laboratory Business Overview
  22. 6.4.3 United Laboratory Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 United Laboratory Biosimilar Insulin Glargine Product Portfolio
  24. 6.4.5 United Laboratory Recent Developments
  25. 6.5 Wockhardt
  26. 6.5.1 Wockhardt Company Information
  27. 6.5.2 Wockhardt Business Overview
  28. 6.5.3 Wockhardt Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Wockhardt Biosimilar Insulin Glargine Product Portfolio
  30. 6.5.5 Wockhardt Recent Developments
  31. 6.6 Eli Lilly
  32. 6.6.1 Eli Lilly Company Information
  33. 6.6.2 Eli Lilly Business Overview
  34. 6.6.3 Eli Lilly Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Eli Lilly Biosimilar Insulin Glargine Product Portfolio
  36. 6.6.5 Eli Lilly Recent Developments
  37. 6.7 Tonghua Dongbao
  38. 6.7.1 Tonghua Dongbao Company Information
  39. 6.7.2 Tonghua Dongbao Business Overview
  40. 6.7.3 Tonghua Dongbao Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Tonghua Dongbao Biosimilar Insulin Glargine Product Portfolio
  42. 6.7.5 Tonghua Dongbao Recent Developments
7 North America by Country
  1. 7.1 North America Biosimilar Insulin Glargine Sales by Country
  2. 7.1.1 North America Biosimilar Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Biosimilar Insulin Glargine Sales by Country (2021-2026)
  4. 7.1.3 North America Biosimilar Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Biosimilar Insulin Glargine Market Size by Country
  6. 7.2.1 North America Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Biosimilar Insulin Glargine Market Size by Country (2021-2026)
  8. 7.2.3 North America Biosimilar Insulin Glargine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Biosimilar Insulin Glargine Sales by Country
  2. 8.1.1 Europe Biosimilar Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Biosimilar Insulin Glargine Sales by Country (2021-2026)
  4. 8.1.3 Europe Biosimilar Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Biosimilar Insulin Glargine Market Size by Country
  6. 8.2.1 Europe Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Biosimilar Insulin Glargine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Biosimilar Insulin Glargine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Biosimilar Insulin Glargine Sales by Country
  2. 9.1.1 Asia-Pacific Biosimilar Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Biosimilar Insulin Glargine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Biosimilar Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Biosimilar Insulin Glargine Market Size by Country
  6. 9.2.1 Asia-Pacific Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Biosimilar Insulin Glargine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Biosimilar Insulin Glargine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Biosimilar Insulin Glargine Sales by Country
  2. 10.1.1 South America Biosimilar Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Biosimilar Insulin Glargine Sales by Country (2021-2026)
  4. 10.1.3 South America Biosimilar Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Biosimilar Insulin Glargine Market Size by Country
  6. 10.2.1 South America Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Biosimilar Insulin Glargine Market Size by Country (2021-2026)
  8. 10.2.3 South America Biosimilar Insulin Glargine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Biosimilar Insulin Glargine Sales by Country
  2. 11.1.1 Middle East and Africa Biosimilar Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Biosimilar Insulin Glargine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Biosimilar Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Biosimilar Insulin Glargine Market Size by Country
  6. 11.2.1 Middle East and Africa Biosimilar Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Biosimilar Insulin Glargine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Biosimilar Insulin Glargine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Biosimilar Insulin Glargine Value Chain Analysis
  2. 12.1.1 Biosimilar Insulin Glargine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Biosimilar Insulin Glargine Production Mode & Process
  7. 12.2 Biosimilar Insulin Glargine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Biosimilar Insulin Glargine Distributors
  10. 12.2.3 Biosimilar Insulin Glargine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst